Alnylam Pharmaceuticals, INC. 8-K Filing
Ticker: ALNY · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1178670
Sentiment: neutral
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2025-12-03 16:49:31
Key Financial Figures
- $0.01 — ange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Sto
- $75,000 — will receive an annual cash retainer of $75,000. In addition, in connection with his el
- $600,000 — ggregate grant date fair value equal to $600,000 using the Company's then-current Black-
- $200,000 — g an aggregate grant date fair value of $200,000 (determined based on the closing price
Filing Documents
- alny-20251202.htm (8-K) — 32KB
- a20251203exhibit991.htm (EX-99.1) — 19KB
- image_0.jpg (GRAPHIC) — 4KB
- 0001628280-25-055084.txt ( ) — 180KB
- alny-20251202.xsd (EX-101.SCH) — 2KB
- alny-20251202_lab.xml (EX-101.LAB) — 22KB
- alny-20251202_pre.xml (EX-101.PRE) — 13KB
- alny-20251202_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 5.02 shall be deemed to be furnished, and not filed: 99.1 Press Release dated December 3 , 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 3, 2025 ALNYLAM PHARMACEUTICALS, INC. By: /s/ Jeffrey V. Poulton Jeffrey V. Poulton Executive Vice President, Chief Financial Officer